BR112018000366A2 - polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão - Google Patents
polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusãoInfo
- Publication number
- BR112018000366A2 BR112018000366A2 BR112018000366A BR112018000366A BR112018000366A2 BR 112018000366 A2 BR112018000366 A2 BR 112018000366A2 BR 112018000366 A BR112018000366 A BR 112018000366A BR 112018000366 A BR112018000366 A BR 112018000366A BR 112018000366 A2 BR112018000366 A2 BR 112018000366A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion polypeptide
- nucleic acid
- methods
- producing
- control points
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 12
- 229920001184 polypeptide Polymers 0.000 title abstract 12
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 12
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 12
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 102000019298 Lipocalin Human genes 0.000 title 1
- 108050006654 Lipocalin Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 230000002924 anti-infective effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15180116 | 2015-08-07 | ||
| EP16150707 | 2016-01-11 | ||
| PCT/EP2016/068860 WO2017025498A1 (en) | 2015-08-07 | 2016-08-08 | Novel fusion polypeptide specific for lag-3 and pd-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018000366A2 true BR112018000366A2 (pt) | 2018-09-11 |
Family
ID=56842783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018000366A BR112018000366A2 (pt) | 2015-08-07 | 2016-08-08 | polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão |
Country Status (13)
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX385338B (es) | 2013-02-22 | 2025-03-18 | CureVac SE | Combinación de vacunación e inhibición de la trayectoria pd-1. |
| HK1250033A1 (zh) | 2015-07-13 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法 |
| AU2017283181B2 (en) | 2016-06-20 | 2024-08-15 | F-Star Therapeutics Limited | Binding molecules binding PD-L1 and LAG-3 |
| CA3027302A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Binding members(1) |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| TWI843168B (zh) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| CA3050614A1 (en) * | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| WO2018222711A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| MX2019012076A (es) | 2017-05-30 | 2019-12-09 | Bristol Myers Squibb Co | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). |
| DK3631454T3 (da) | 2017-05-30 | 2023-12-04 | Bristol Myers Squibb Co | Behandling af lag-3 positive tumorer |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| JP2021511793A (ja) * | 2018-01-31 | 2021-05-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体 |
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| EP3768727A4 (en) * | 2018-03-20 | 2021-12-22 | Wuxi Biologics Ireland Limited. | NEW BIS SPECIFIC PD-1 / LAG-3 ANTIBODY MOLECULES |
| US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| EP3820898B1 (en) | 2018-07-12 | 2025-09-03 | invoX Pharma Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| WO2020021061A1 (en) * | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
| CA3107660A1 (en) | 2018-07-26 | 2020-01-30 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
| PT4445958T (pt) | 2018-10-19 | 2025-11-26 | Bristol Myers Squibb Co | Terapia de associação para melanoma |
| MX2021005394A (es) | 2018-11-07 | 2021-07-06 | Merck Sharp & Dohme Llc | Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1). |
| WO2020127369A1 (en) * | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
| KR20210108978A (ko) * | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
| CN109912717B (zh) * | 2019-03-04 | 2020-05-26 | 北京天广实生物技术股份有限公司 | 结合cd40的抗体及其用途 |
| CN111763261B (zh) * | 2019-04-02 | 2022-08-09 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN114127315A (zh) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法 |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| CN112079925B (zh) * | 2019-06-13 | 2025-04-25 | 上海健信生物医药科技有限公司 | 靶向lag-3的抗体和双特异性抗体及其用途 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20220348653A1 (en) | 2019-09-22 | 2022-11-03 | Bristol-Myers Squibb Company | Quantitative Spatial Profiling for LAG-3 Antagonist Therapy |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| JP2023500156A (ja) * | 2019-11-08 | 2023-01-04 | チャンスー シムサー ファーマシューティカル カンパニー リミテッド | 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途 |
| CN115942973A (zh) | 2019-11-08 | 2023-04-07 | 百时美施贵宝公司 | 用于黑色素瘤的lag-3拮抗剂疗法 |
| KR20220139915A (ko) | 2020-02-06 | 2022-10-17 | 브리스톨-마이어스 스큅 컴퍼니 | Il-10 및 그의 용도 |
| CN111533782A (zh) * | 2020-05-08 | 2020-08-14 | 中国药科大学 | 一种靶向免疫检查点lag-3的活性多肽及其应用 |
| US11338040B2 (en) * | 2020-06-04 | 2022-05-24 | Leidos, Inc. | Immunomodulatory compounds |
| WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| CA3193421A1 (en) | 2020-08-28 | 2022-03-03 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| US20230303700A1 (en) | 2020-08-31 | 2023-09-28 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| FI4267105T3 (fi) | 2020-12-28 | 2025-06-17 | Bristol Myers Squibb Co | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| JP2024506839A (ja) | 2021-01-29 | 2024-02-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | キナーゼ阻害剤を用いてがんを処置する方法 |
| CN112500489B (zh) * | 2021-02-07 | 2021-05-04 | 天津一瑞生物科技股份有限公司 | 一种抗oxa-23型碳青霉烯酶杂交瘤细胞株，单克隆抗体及应用 |
| AU2022246593A1 (en) | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| AU2022253474A1 (en) | 2021-04-08 | 2023-11-16 | Board Of Regents, The University Of Texas System | Compounds and methods for theranostic targeting of parp activity |
| WO2022240741A1 (en) | 2021-05-12 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof |
| US20240327544A1 (en) | 2021-07-13 | 2024-10-03 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CA3224890A1 (en) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| JP2025503962A (ja) | 2022-01-26 | 2025-02-06 | ブリストル－マイヤーズ スクイブ カンパニー | 肝細胞がんのための併用療法 |
| IL314713A (en) | 2022-02-25 | 2024-10-01 | Bristol Myers Squibb Co | Combined therapy for colorectal carcinoma |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| US20250179170A1 (en) | 2022-03-08 | 2025-06-05 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| IL317319A (en) | 2022-06-02 | 2025-01-01 | Bristol Myers Squibb Co | Antibody compounds and methods of using them |
| EP4624487A1 (en) * | 2022-11-24 | 2025-10-01 | Tokushima University | Production of antibodies against protein |
| AU2023403103A1 (en) | 2022-12-01 | 2025-07-10 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| AU2023393653A1 (en) | 2022-12-14 | 2025-05-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| KR20250123912A (ko) | 2022-12-21 | 2025-08-18 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 병용 요법 |
| CN115960269A (zh) * | 2023-01-30 | 2023-04-14 | 上海甲贝医药科技有限公司 | 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| WO2025184211A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| NZ601439A (en) | 2005-06-08 | 2012-11-30 | Brigham & Womens Hospital | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| CA2936611A1 (en) * | 2014-01-13 | 2015-07-16 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CA3175979A1 (en) | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
-
2016
- 2016-08-08 EA EA201890456A patent/EA201890456A1/ru unknown
- 2016-08-08 BR BR112018000366A patent/BR112018000366A2/pt not_active Application Discontinuation
- 2016-08-08 CA CA2994631A patent/CA2994631A1/en not_active Abandoned
- 2016-08-08 KR KR1020187006631A patent/KR20180035906A/ko not_active Withdrawn
- 2016-08-08 HK HK18113535.5A patent/HK1254450A1/zh unknown
- 2016-08-08 RU RU2018107991A patent/RU2018107991A/ru not_active Application Discontinuation
- 2016-08-08 AU AU2016306597A patent/AU2016306597A1/en not_active Abandoned
- 2016-08-08 WO PCT/EP2016/068860 patent/WO2017025498A1/en not_active Ceased
- 2016-08-08 EP EP16757830.1A patent/EP3331901A1/en not_active Withdrawn
- 2016-08-08 JP JP2018506260A patent/JP2018526989A/ja not_active Withdrawn
- 2016-08-08 US US15/750,651 patent/US20190010231A1/en not_active Abandoned
- 2016-08-08 MX MX2018001567A patent/MX2018001567A/es unknown
- 2016-08-08 CN CN201680046086.9A patent/CN107922470A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018107991A3 (cg-RX-API-DMAC7.html) | 2020-02-17 |
| RU2018107991A (ru) | 2019-09-09 |
| EA201890456A1 (ru) | 2018-07-31 |
| MX2018001567A (es) | 2018-11-09 |
| JP2018526989A (ja) | 2018-09-20 |
| CA2994631A1 (en) | 2017-02-16 |
| WO2017025498A1 (en) | 2017-02-16 |
| US20190010231A1 (en) | 2019-01-10 |
| CN107922470A (zh) | 2018-04-17 |
| AU2016306597A1 (en) | 2018-02-22 |
| KR20180035906A (ko) | 2018-04-06 |
| EP3331901A1 (en) | 2018-06-13 |
| HK1254450A1 (zh) | 2019-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018000366A2 (pt) | polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão | |
| EP4378962A3 (en) | Anti-cancer fusion polypeptide | |
| BR112017015773A2 (pt) | muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo | |
| MX2017014082A (es) | Nuevas proteinas especificas para cd137. | |
| BR112017026292A2 (pt) | muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico | |
| BR112018017031A2 (pt) | formulações de antagonista de il-6 e usos das mesmas | |
| BR112017017530A2 (pt) | proteínas específicas para pioverdina e pioquelina | |
| BR112018068363A2 (pt) | fármaco terapêutico indutor de dano celular para uso em terapia de câncer | |
| BR112014022932A2 (pt) | molécula de ligação, seu uso e seu método de produção, molécula de ácido nucleico, vetor, célula hospedeira, e composição | |
| BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
| BR112018011002A2 (pt) | variantes de fgf21 | |
| BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
| BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
| BR112013026976A2 (pt) | alfa glucosidade ácida modificada com processamento acelerado | |
| BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
| MX2017014730A (es) | Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3). | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| BR112018077139A8 (pt) | Anticorpos anti-met e seus usos | |
| BR112018077225A2 (pt) | proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas | |
| BR112018010887A2 (pt) | polipeptídeo de fusão | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| BR112018006572A2 (pt) | terapia de combinação racional para o tratamento de câncer | |
| BRPI1007979A2 (pt) | Anticorpos anti-mst1r e usos dos mesmos | |
| BR112017002166A2 (pt) | terapias antibióticas de peptídeos derivados do búfalo d?água | |
| BR112016008086A2 (pt) | Glicoproteínas recombinantes e usos das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |